Gene fuelled transporter causes breast cancer cells to self-destruct

Feb 28, 2011

Scientists at Queen's University Belfast have shown that they can deliver a gene directly into breast cancer cells causing them to self-destruct, using an innovative, miniscule gene transport system, according to research published today (28 February) in the International Journal of Pharmaceutics.

Using a transport system called a Designer Biomimetic Vector (DBV), Dr Helen McCarthy, from Queen's School of Pharmacy, funded by Campaign, packaged a gene into a nanoparticle 400 times smaller than the width of a human hair, allowing it to be delivered straight into in the laboratory.

The gene called iNOS, is targeted specifically to breast cancer cells using the DBV where it forces the cells to produce poisonous ; either killing the cells outright or making them more vulnerable to being destroyed by chemotherapy and . As this approach leaves normal healthy breast cells unaffected, this would overcome many of the toxic side effects of current treatments.

Further investigation is needed but it could be trialled in patients in as little as five years. Dr McCarthy's next step is to turn the into a dried powder that could be easily transported and reconstituted before being given to patients.

Dr McCarthy said: "A major stumbling block to using gene therapy in the past has been the lack of an effective delivery system. Combining the Designer Biomimetic Vector with the iNOS gene has proved successful in killing breast cancer cells in the laboratory. In the long term, I see this being used to treat people with metastatic breast cancer that has spread to the bones, ideally administered before radiotherapy and chemotherapy."

Dr Lisa Wilde, Research Information Senior Manager, Breast Cancer Campaign said: " could potentially be an exciting avenue for treating breast cancer. Although at an early stage, Dr McCarthy's laboratory research shows that this system for delivering toxic genes to tumour cells holds great promise and we look forward to seeing how it is translated into patients."

Explore further: Survival differences seen for advanced-stage laryngeal cancer

Provided by Queen's University Belfast

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Gene study offers new target for breast cancer drugs

Aug 05, 2010

(PhysOrg.com) -- A gene called POLQ is linked to an eight-fold risk of breast cancer returning, according to Oxford University research published in the journal OncoTarget. Developing drugs to block POLQ could increase surviv ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

Hospital volume not linked to costs of cancer surgery

Nov 26, 2014

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.